versión imprimible

BCMA Targeted Therapies

Evvnt Promotion / evvnt
21.06.2021 - 23.06.2021  Online
Time: 09:00 - 16:00
Temas de la conferencia
Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.
Organizador profesional (PCO)
Hanson Wade
Speakers: Adam Cohen, Assistant Professor - Medicine, University of Pennsylvania, Andreas Pahl, Chied Scientific Officer, Heidelbeg Pharma, David DiLillo, Assoc. Director, Immuno-Oncology, Regeneron and more.

Información e inscripción:
Mr. Customer Service
Medicina General
Cuota del Congreso
USD 1799.0 - USD 3237.0
Los participantes esperaban
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Hilfswerk AustriaAMREF - African Medical and Research FoundationSwiss Tropical and Public Health InstituteÄrzte der WeltÖsterreichisches Rotes KreuzÖsterreichische Gesellschaft für Public HealthÖsterreichische Akademie der ÄrzteCharité International Academy